[Remicade in therapy of rheumatoid arthritis and Crohn diseases--no reason for panic].
Kalden
J R
JR
Medizinische Klinik III mit Poliklinik Universitätsklinikum und Institut für Klinische Immunologie, Friedrich-Alexander-Universität Erlangen-Nürnberg.
Lochs
H
H
Wollheim
H
H
D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D002423:Cause of Death; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005858:Germany; D006801:Humans; D000069285:Infliximab; D009894:Opportunistic Infections / Q000139:chemically induced / Q000276:immunology / Q000401:mortality; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab